Intraperitoneal administration of Taxol in the management of ovarian cancer - PubMed (original) (raw)
Affiliations
- PMID: 7912515
Review
Intraperitoneal administration of Taxol in the management of ovarian cancer
M Markman et al. J Natl Cancer Inst Monogr. 1993.
Abstract
The safety and pharmacology of the intraperitoneal administration of Taxol was evaluated by treatment of 25 patients (24 with ovarian cancer) on a phase I dose-escalation trial. The drug was delivered in 2 L of normal saline every 3 to 4 weeks, with a starting dose of 25 mg/m2. The dose-limiting toxicity was abdominal pain at Taxol doses greater than 125 mg/m2. A 3-log pharmacokinetic advantage for peritoneal cavity exposure to Taxol, compared to the systemic compartment, was demonstrated following intraperitoneal delivery. In addition, high levels of Taxol persisted within the cavity for more than 48 hours following a single treatment. Despite the major pharmacokinetic advantage for peritoneal cavity exposure, significant concentrations of Taxol were demonstrated within the systemic compartment after intraperitoneal treatment. Several patients exhibited clinical and laboratory evidence of an antitumor response. Further exploration of a possible role for the intraperitoneal administration of Taxol in the management of ovarian cancer appears indicated.
Similar articles
- Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Markman M, Francis P, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, et al. Markman M, et al. Ann Oncol. 1994;5 Suppl 6:S55-8. Ann Oncol. 1994. PMID: 7865436 Clinical Trial. - Intraperitoneal paclitaxel in the management of ovarian cancer.
Markman M. Markman M. Semin Oncol. 1995 Oct;22(5 Suppl 12):86-7. Semin Oncol. 1995. PMID: 7481868 Clinical Trial. - Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
Markman M, Francis P, Rowinsky E, Hoskins W. Markman M, et al. Semin Oncol. 1995 Jun;22(3 Suppl 6):84-7. Semin Oncol. 1995. PMID: 7597437 Review. - A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK, Fleming GF, Markman M, Bailey HH. Armstrong DK, et al. Gynecol Oncol. 2006 Nov;103(2):391-6. doi: 10.1016/j.ygyno.2006.02.029. Epub 2006 Apr 19. Gynecol Oncol. 2006. PMID: 16626792 Clinical Trial. - Taxol: an important new drug in the management of epithelial ovarian cancer.
Markman M. Markman M. Yale J Biol Med. 1991 Nov-Dec;64(6):583-90. Yale J Biol Med. 1991. PMID: 1687343 Free PMC article. Review.
Cited by
- Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.
Eskander RN, Cripe J, Bristow RE. Eskander RN, et al. Curr Treat Options Oncol. 2014 Mar;15(1):27-40. doi: 10.1007/s11864-013-0264-2. Curr Treat Options Oncol. 2014. PMID: 24338278 Review. - Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. ten Tije AJ, et al. Clin Pharmacokinet. 2003;42(7):665-85. doi: 10.2165/00003088-200342070-00005. Clin Pharmacokinet. 2003. PMID: 12844327 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical